Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR) (R43/R44 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to encourage New or Renewal Small Business Innovation Research (SBIR) grant applications focused on specific product development activities for radiological/nuclear medical countermeasures leading to Investigational New Drug (IND) or Investigational Device Exemption (IDE) submission packages to the U.S. Food and Drug Administration. 

Deadlines: Sep. 5, Jan. 5, Apr. 5

PA-18-525 Expiration Date January 6, 2021 

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

Amount Description

Budgets up to $300,000 total costs per year for Phase I and up to $1,000,000 total costs per year for Phase II may be requested.

Funding Type

Grant

Eligibility

Faculty

Category

Engineering and Physical Sciences
Medical
Medical - Clinical Science
Medical - Translational

External Deadline

January 5, 2021